not used title

not used title

This month, we’re celebrating National Immunization Awareness Month! Although children may come to mind first when we think of vaccination, access to immunization is just as important for older Americans.

According to the Centers for Disease Control and Prevention (CDC), some childhood vaccines can become less effective over time. The U.S. Department of Health and Human Services urges seniors to get vaccinated for the flu, tetanus, hepatitis A and B, pertussis (commonly known as whooping cough), pneumococcal, meningococcal, shingles and more.

It’s estimated that following the full immunization schedule from birth benefits society by saving 33,000 lives and $33.4 billion in indirect health care costs in the United States. However, vaccination coverage among American adults remains low, so thousands still die each year from vaccine-preventable diseases. Medicare Part D covers many of these critical vaccines, and the Centers for Medicare & Medicaid Services has encouraged Part D plans to offer either zero or low cost sharing for vaccines to help increase adult immunization rates.

Ensuring seniors have affordable access to vaccines is increasingly important as new, innovative immunizations are closer and closer to being available. Take, for example, HIV. There are 16 vaccines for HIV currently in development, including additional combination treatments, more effective therapies and preventative vaccines. Or look at cancer – there are currently 96 cancer vaccines in development harnessing the body’s own immune system to protect against the disease.  

Biopharmaceutical researchers are pursuing new techniques and strategies in vaccine development, such as the use of genomics, to address these and other challenges, creating new opportunities to protect against many more life-threatening diseases in the future.

Watch this video to learn more about progress in developing new vaccines:

Nicole Longo

Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Nicole Longo

Author Twitter

Author LinkedIn

What AARP isn’t telling seniors about MFN

August 24, 2026

CMS proposal could discourage patient-centered innovation

August 18, 2026

Nearly 1 in 4 patients initially denied access to IRA medicines

August 6, 2026

Why smart vaccine policy matters

August 3, 2026

Medicare Part D at 20: Building on a strong foundation

July 23, 2026

New study: HPV vaccination helps prevent cervical cancer deaths

July 21, 2026

New research reinforces the importance of hepatitis B vaccination at birth

May 21, 2026

MFN won’t lower costs when insurers call the shots

May 8, 2026

Guest Blog: How MFN price controls could decide my health care

April 30, 2026

World Immunization Week: Putting preventable diseases in the past

April 24, 2026

States should avoid repeating the IRA’s price‑setting mistakes 

April 21, 2026

ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years

April 15, 2026

Insurers routinely block seniors’ access to medicines in Medicare Part D

March 18, 2026

MFN undermines U.S. biopharmaceutical innovation

February 25, 2026

CMS puts patients and innovation at risk with MFN

February 24, 2026

Why shifting childhood vaccines to “shared clinical decision-making” puts kids at risk

February 23, 2026

New list of selected drugs highlights growing consequences of government price setting

January 28, 2026

Changes to America’s childhood vaccine schedule fail to protect our nation's kids

January 13, 2026

Guest blog: Making the most of the Medicare Prescription Payment Plan

December 8, 2025

The IRA’s price setting doesn’t guarantee lower costs or better access

November 17, 2025

New study: Measles setbacks harm health and America’s economy

October 28, 2025

Why the hepatitis B vaccine matters

October 21, 2025

What seniors can expect this open enrollment

October 14, 2025

Part D premiums are going up, while choices are going down

October 8, 2025

Vaccines and autism: Decades of scientific evidence find no link

September 22, 2025

Delivering breakthroughs and lower costs for patients

September 8, 2025

Why the vaccine injury program matters

August 18, 2025

Recognizing the importance of vaccination for American health and security

August 4, 2025

Celebrating 60 Years of Medicare

July 30, 2025

Medicare patients face higher drug costs, despite IRA promises

July 22, 2025

Answering common questions on mRNA technology

July 17, 2025

What to know about vaccine ingredients: Aluminum and thimerosal

June 24, 2025

Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas

June 16, 2025

PBMs launch new ad campaign to block reforms

May 5, 2025

World Immunization Week: Highlighting the importance of vaccines for public health

April 28, 2025

What you need to know: Measles and the MMR vaccine

March 10, 2025

Improved treatments continue to lead to declining cancer mortality rates in the U.S.

February 25, 2025

CMS, don’t fall behind the rest of the medical community on obesity

February 14, 2025

Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024

February 3, 2025

Patients are losing as government price setting continues

January 17, 2025

A new administration poses new opportunities for patient access

December 17, 2024

Recognizing the value of disease prevention with Dr. Len Friedland from GSK

December 12, 2024

CMS needs to do better

November 4, 2024

Leveraging the power of vaccines to prevent antimicrobial resistance

October 31, 2024

From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting

October 30, 2024

The Patient Perspective: Vaccines

October 23, 2024

Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?

October 18, 2024

Did the administration consider the importance of blood cancer medicines to patients in price setting process?

October 8, 2024

New Report: Tackling chronic conditions with preventive treatment

September 30, 2024

Did the administration consider the importance of blood clot medicines to patients in the price setting process?

September 25, 2024

The Inflation Reduction Act could increase costs and reduce access for millions of seniors

September 17, 2024

Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.

September 16, 2024

Did the administration consider the value of innovative diabetes medicines in price setting process?

August 28, 2024

How to protect your children’s health this school year

August 22, 2024

New survey: Insurers confirm IRA will reduce patient treatment options

August 20, 2024

The unintended consequences of government price setting in Medicare Part D

August 16, 2024

Don’t put the government between patients and their medicines

August 7, 2024

What is the low-income subsidy program and how is it changing?

July 31, 2024

Case study: How seniors could face access disruptions because of the IRA’s price setting provisions

July 22, 2024

New Report: Vaccines continue to drive improved health outcomes

July 16, 2024

PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm

July 3, 2024

Showcasing the promise of biopharma at ASCO 2024

June 28, 2024

The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026

June 25, 2024

Mental Health Awareness Month: Supporting loved ones and improving mental health in America

May 28, 2024

IRA is already negatively impacting access to medicines in Part D

April 25, 2024

New study finds insurers and PBMs increasing access restrictions in Medicare Part D

April 16, 2024

World Vaccine Congress: Building on vaccine success

April 1, 2024

As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind

February 1, 2024

WHO Pandemic Agreement offers opportunities and risks for American innovators

November 20, 2023

New Report: 1,600 cancer treatments and vaccines in clinical development

November 9, 2023

ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference

November 6, 2023

What you should know about protecting your health this fall

October 16, 2023

ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs

September 28, 2023

IRA threatens seniors’ access to robust treatment options

September 26, 2023

Medicare Prescription Payment Plan will benefit patients if implemented correctly

September 21, 2023

Correcting the record: IRA’s government price setting provisions are unconstitutional

September 8, 2023

IRA changes to Part D risk access to medicines

August 24, 2023

With the first list of medicines out, let’s not forget why government price setting is bad policy

August 22, 2023

One year later IRAs unintended consequences are becoming reality

August 16, 2023

AARP’s latest misleading report

August 11, 2023

A conversation with Dr. Mike Ybarra on the current state of COVID-19

June 27, 2023

Four things for CMS to keep in mind as they implement changes to Part D

June 7, 2023

Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation

May 11, 2023

Support for continued progress is critical for pediatric drug development

May 8, 2023

CMS guidance on IRA price setting process doubles down on bad policy

April 14, 2023

A guide to MedPAC’s Part B vote today

April 13, 2023

What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary

April 13, 2023

MedPAC proposal threatens access to medicines in Part B

April 6, 2023

CMS coverage policy is detrimental to Alzheimer’s patients

April 4, 2023

How Part B’s ASP system helps control costs for the government and seniors

March 30, 2023

PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement

March 30, 2023

New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans

March 28, 2023

Medicare Part B spending in four points

March 28, 2023

Celebrating the success of the COVID-19 vaccines, and looking to the future

March 27, 2023

What we’ve learned from three years of fighting COVID-19

March 20, 2023

State policymakers can protect American innovation and help Americans live longer, healthier lives

February 9, 2023

Recognizing National Glaucoma Awareness Month

February 1, 2023

New Report More than 160 medicines in development for mental illness

January 26, 2023

ICYMI: Cancer death rate continues to decline due to treatment advances

January 25, 2023

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

December 1, 2022

Word of the Month: What is TRIPS?

November 29, 2022

Medicare Part D open enrollment and what recent changes mean for beneficiaries

November 17, 2022

What you should know about RSV

November 15, 2022

Word of the Month: Long COVID

October 19, 2022

Many seniors are paying more for Part D medicines than their insurer

October 18, 2022

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

October 13, 2022

Busting 3 Myths About Copay Coupons

October 5, 2022

New Report: Nearly 800 medicines in development to treat chronic conditions

September 29, 2022

A key fact the White House is reluctant to admit

September 27, 2022

A key fact the White House is reluctant to admit

September 27, 2022

Recognizing National Sickle Cell Awareness Month

September 23, 2022

Partnerships are driving global COVID-19 treatment access

September 22, 2022

CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease

September 1, 2022

Myth vs. Fact: The Senate’s latest price setting proposal

August 5, 2022

The Senate’s latest price setting proposal will undermine U.S. economic growth

August 3, 2022

Celebrating Medicare’s 57th anniversary

August 2, 2022

The Senate’s latest price setting proposal will undermine: Our health care system

July 28, 2022

The Senate’s latest price setting proposal will undermine: Patient access to medicines

July 26, 2022

New research shows competition driven by biosimilars helps control costs in Part B

July 19, 2022

ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

July 15, 2022

Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients

July 12, 2022

CMS coverage decision restricts access to treatments for Alzheimer’s disease

June 22, 2022

Potential gene therapies bring hope to patients with sickle cell disease

June 6, 2022

Gene therapies can reduce treatment burden and costs for patients with blood disorders

May 18, 2022

Report: More than 500 medicines in development to treat disorders of the blood

May 18, 2022

Annual projections from NHE compared to actual health care spending

May 5, 2022

Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

April 27, 2022

Part D 101: Three charts show how the program provides comprehensive prescription drug coverage

April 26, 2022

Report: More than 600 medicines in development for diseases affecting women

March 31, 2022

New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year

February 24, 2022

Government price setting leaves behind families counting on new medicines

February 23, 2022

What you need to know about newly authorized COVID-19 antiviral treatments

February 22, 2022

Part B 101: Three charts show the program helps control costs for health care system and enrollees

February 18, 2022

Guest Blog: COVID-19 vaccines are the key to keeping kids healthy

February 16, 2022

PhRMA submits comments urging CMS to withdraw coverage proposal

February 11, 2022

Government price setting won’t stop insurers from shifting costs to patients

February 2, 2022

Research and development continues long after a medicine is initially approved

February 1, 2022

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

January 25, 2022

Post-approval research save lives. Why is Congress trying disincentivize it?

December 17, 2021

New Report: Nearly 800 new medicines in development to treat rare diseases

December 16, 2021

A price control by any other name would still put patients at risk and threaten innovation

December 9, 2021

Making medicines more affordable: Making insurance work like insurance

December 8, 2021

3 things to know about the importance of post-approval research and development

December 6, 2021

New data show insurers and PBMs increase barriers to care

December 2, 2021

Global COVID-19 vaccination matters now and for the future

November 29, 2021

Guest post: Congress should not put future innovation at risk

November 29, 2021

What is missing in the current drug pricing plan

November 23, 2021

ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

November 19, 2021

Three things to know about so-called Medicare negotiation polling

November 18, 2021

In the current health care debate, Congress has lost sight of what matters to U.S. voters

November 15, 2021

Making medicines more affordable: Modernizing Medicare

November 11, 2021

Understanding breakthrough COVID-19 infections

November 11, 2021

What they are saying: Government price setting for medicines is not the answer

November 4, 2021

Guest post: Continued research and development is critical for ALS patients and families

October 25, 2021

CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018

October 19, 2021

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

October 18, 2021

New poll shows Americans reject Medicare negotiation once they learn more about the policy

October 15, 2021

New report shows more than 260 medicines in development to fight neurodegenerative diseases

October 12, 2021

What is Kaiser Family Foundation up to?

October 12, 2021

The important role of antivirals in the fight against COVID-19

October 6, 2021

Industry leaders discuss the impact of the drug pricing debate

September 23, 2021

Five reasons tying VA prices to Medicare Part D misses the mark

September 22, 2021

America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach

September 15, 2021

A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19

September 8, 2021

Recognizing National Immunization Awareness Month

August 31, 2021

Recent polling misrepresents public support for Medicare “negotiation”

August 31, 2021

Driving further innovation is critical to global vaccine equity

August 24, 2021

What they’re saying: Patient advocates want to protect Medicare from government interference

August 24, 2021

Myth vs. fact: Polling and Medicare “negotiation”

August 12, 2021

Supporting country readiness to boost global vaccine access

August 12, 2021

Ensuring global vaccine equity requires eliminating trade and regulatory barriers

August 5, 2021

ICYMI: Event spotlights how we can make Medicare work better for patients

August 4, 2021

Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine

August 4, 2021

The future of the rebate rule: Will policymakers stand with patients?

August 2, 2021

Celebrating Medicare’s 56th anniversary

July 30, 2021

Increasing global access to vaccines by optimizing production

July 29, 2021

Government “negotiation” could have devastating consequences for Medicare enrollees

July 23, 2021

Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief

July 23, 2021

Guest Post: A patient’s story of the long-term health impacts of COVID-19

July 21, 2021

Protecting Medicare from government interference

July 21, 2021

Dose sharing as a part of the COVID-19 global vaccine equity strategy

July 20, 2021

Promoting global vaccine equity while protecting innovation

July 15, 2021

Data shows voters strongly support protecting access to their medicines

July 15, 2021

Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery

July 2, 2021

Medicare “negotiation” proposals threaten Americans’ access to medicines

June 30, 2021

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities

June 22, 2021

Americans 12 years of age and older are eligible for COVID-19 vaccines

June 17, 2021

Out-of-pocket trends in Medicare Part D show rising costs for seniors

May 24, 2021

ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios

May 21, 2021

Supporting India during the devastating coronavirus surge

May 20, 2021

The ABCs (and Ds) of Medicare

May 13, 2021

PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines

May 6, 2021

Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community

May 5, 2021

New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections

April 29, 2021

Patient safety is at the heart of COVID-19 vaccine R&D

April 26, 2021

Data shows that Americans are relying on vaccines to get us through the pandemic

April 22, 2021